SCHEMBL11028813

SCHEMBL11028813

C=C(c1ccccc1)c1cnc(C(N)=O)c(Nc2ccc(N3CCN(C)CC3)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 2/20 0.53
▸ CDK4 P11802 3/20 0.50
▸ CDK6 Q00534 2/20 0.50
▸ CCND1 P24385 2/20 0.50
▸ STAT6 P42226 1/20 0.50
▸ CCNT1 O60563 1/20 0.50
▸ CDK9 P50750 1/20 0.50
▸ CDK11A Q9UQ88 1/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ BRD4 O60885 1/20 0.48
▸ LCK P06239 1/20 0.48
▸ KDR P35968 1/20 0.48
▸ MAPK14 Q16539 1/20 0.48
▸ EGFR P00533 1/20 0.47
▸ ALK Q9UM73 2/20 0.47
▸ INSR P06213 1/20 0.47
▸ MAPKAPK2 P49137 1/20 0.47
▸ BTK Q06187 2/20 0.47
▸ TNIK Q9UKE5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11031861 0.85 SLC2A1 (0.55) SLC2A1CDK4CDK6CCND1STAT6
SCHEMBL11029599 0.84 MAPKAPK2 (0.58) SLC2A1CDK4CDK6CCND1STAT6
SCHEMBL11031445 0.81 SLC2A1 (0.51) SLC2A1CDK4CDK6CCND1CCNT1
SCHEMBL11295065 0.81 STAT6 (0.55) SLC2A1CDK4CDK6CCND1STAT6
SCHEMBL11030040 0.81 SLC2A1 (0.51) SLC2A1CDK4CDK6CCND1STAT6
SCHEMBL11030049 0.81 SLC2A1 (0.51) SLC2A1CDK4CDK6CCND1STAT6
SCHEMBL11033999 0.81 SLC2A1 (0.51) SLC2A1CDK4CDK6CCND1STAT6
SCHEMBL11025081 0.81 STAT6 (0.55) SLC2A1CDK4CDK6CCND1STAT6
SCHEMBL11027974 0.80 SLC2A1 (0.54) SLC2A1CDK4CDK6STAT6LCK
SCHEMBL23080983 0.79 LCK (0.54) SLC2A1CDK4CDK6STAT6LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 SLC2A1 3662/4885CDK4 78/4885CDK6 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback